CA3078568A1 - Composition de comprime a liberation modifiee comprenant du mirabegron - Google Patents

Composition de comprime a liberation modifiee comprenant du mirabegron Download PDF

Info

Publication number
CA3078568A1
CA3078568A1 CA3078568A CA3078568A CA3078568A1 CA 3078568 A1 CA3078568 A1 CA 3078568A1 CA 3078568 A CA3078568 A CA 3078568A CA 3078568 A CA3078568 A CA 3078568A CA 3078568 A1 CA3078568 A1 CA 3078568A1
Authority
CA
Canada
Prior art keywords
tablet
modified release
mirabegron
composition according
release tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3078568A
Other languages
English (en)
Inventor
Agnes Fernandez Pena
Onne Peter Hilbert Backers
Jose VELADA CALZADA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthon BV
Original Assignee
Synthon BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP17196234.3A external-priority patent/EP3292864A1/fr
Priority claimed from US15/730,988 external-priority patent/US10478399B2/en
Application filed by Synthon BV filed Critical Synthon BV
Publication of CA3078568A1 publication Critical patent/CA3078568A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique, en particulier une composition de comprimé à libération modifiée comprenant du mirabegron ou un sel pharmaceutiquement acceptable de celui-ci, ainsi qu'un procédé de préparation d'une telle composition.
CA3078568A 2017-10-12 2017-12-14 Composition de comprime a liberation modifiee comprenant du mirabegron Abandoned CA3078568A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17196234.3 2017-10-12
US15/730,988 2017-10-12
EP17196234.3A EP3292864A1 (fr) 2017-10-12 2017-10-12 Composition de comprimé à libération modifiée comprenant mirabegron
US15/730,988 US10478399B2 (en) 2017-10-12 2017-10-12 Modified release tablet composition comprising mirabegron
PCT/EP2017/082896 WO2019072404A1 (fr) 2017-10-12 2017-12-14 Composition de comprimé à libération modifiée comprenant du mirabegron

Publications (1)

Publication Number Publication Date
CA3078568A1 true CA3078568A1 (fr) 2019-04-18

Family

ID=60702778

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3078568A Abandoned CA3078568A1 (fr) 2017-10-12 2017-12-14 Composition de comprime a liberation modifiee comprenant du mirabegron

Country Status (3)

Country Link
EP (1) EP3694492A1 (fr)
CA (1) CA3078568A1 (fr)
WO (1) WO2019072404A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230157962A1 (en) * 2020-05-17 2023-05-25 Zim Laboratories Limited Novel extended release composition of 2-(2- aminothiazol-4-yl)-n-[4-(2{[(2r)-2-hydroxy-2-phenylethyl] amino} ethyl) phenyl] acetamide

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4338729A1 (fr) 2022-09-19 2024-03-20 Sanovel Ilac Sanayi Ve Ticaret A.S. Comprimé comprenant du mirabegron
EP4410279A1 (fr) 2023-01-25 2024-08-07 Sanovel Ilac Sanayi Ve Ticaret A.S. Comprimé de film comprenant du mirabegron

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK281042B6 (sk) 1992-09-18 2000-11-07 Yamanouchi Pharmaceutical Co., Ltd Prípravok hydrogélového typu s ustáleným uvoľňovaním
ATE266639T1 (de) 1997-10-17 2004-05-15 Yamanouchi Pharma Co Ltd Amidderivate oder deren salze
JP2005512997A (ja) 2001-11-07 2005-05-12 シントン・ベスローテン・フェンノートシャップ タムスロシン錠
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
EP2832730A4 (fr) * 2012-03-30 2015-09-09 Astellas Pharma Inc Composition pharmaceutique contenant du mirabegron
CN104352475A (zh) * 2014-12-05 2015-02-18 安徽联创生物医药股份有限公司 一种米拉贝隆缓释片及其制备方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230157962A1 (en) * 2020-05-17 2023-05-25 Zim Laboratories Limited Novel extended release composition of 2-(2- aminothiazol-4-yl)-n-[4-(2{[(2r)-2-hydroxy-2-phenylethyl] amino} ethyl) phenyl] acetamide
US12605340B2 (en) * 2020-05-17 2026-04-21 Zim Laboratories Limited Extended release composition of 2-(2-Aminothiazol-4-yl)-N-[4-(2{[(2R)-2-hydroxy-2-phenylethyl] amino} ethyl) phenyl] acetamide

Also Published As

Publication number Publication date
EP3694492A1 (fr) 2020-08-19
WO2019072404A1 (fr) 2019-04-18

Similar Documents

Publication Publication Date Title
US10543174B2 (en) Modified release tablet composition comprising mirabegron
US10478399B2 (en) Modified release tablet composition comprising mirabegron
RS52057B (sr) Formulacija tablete sa produženim oslobađanjem koja sadrži pramipeksol ili njegovu farmaceutski prihvatljivu so
US20190307696A1 (en) Tablets comprising mirabegron and solifenacin
EP4103158B1 (fr) Composition comprenant du ramipril et de l'indapamide
EP3292864A1 (fr) Composition de comprimé à libération modifiée comprenant mirabegron
CA3078568A1 (fr) Composition de comprime a liberation modifiee comprenant du mirabegron
AU2014237934B2 (en) Controlled release pharmaceutical dosage forms
EP2386302A1 (fr) Forme pharmaceutique à libération prolongée de trimetazidine et ses procédés de préparation
CA2895881A1 (fr) Composition de comprime comprenant du chlorhydrate de cinacalcet
EP3697392B1 (fr) Comprimés comprenant de la tamsulosine et de la solifénacine
EP4659745A1 (fr) Comprimé tricouche à double libération de brivaracétam et son procédé de préparation
JP5124286B2 (ja) 徐放性製剤およびその製造方法
US12605340B2 (en) Extended release composition of 2-(2-Aminothiazol-4-yl)-N-[4-(2{[(2R)-2-hydroxy-2-phenylethyl] amino} ethyl) phenyl] acetamide
EP2805714B1 (fr) Composition pharmaceutique stable comprenant de la rosuvastatine calcique amorphe
US20120178810A1 (en) Extended release formulation of an antiepileptic agent
EP4159199A1 (fr) Formulation combinée de mirabegron et de solifénacine
EP3518904A1 (fr) Composition pharmaceutique comprenant du deferasirox
EP4338729A1 (fr) Comprimé comprenant du mirabegron
EP4410279A1 (fr) Comprimé de film comprenant du mirabegron
WO2024063734A1 (fr) Comprimé comprenant du mirabégron
EP4674408A1 (fr) Composition de comprimé à libération modifiée comprenant du mirabegron
US20080206338A1 (en) Controlled release formulations of an alpha-adrenergic receptor antagonist
WO2022254017A1 (fr) Compositions de tofacitinib à libération prolongée
RU2790166C2 (ru) Оральные дозированные формы тофацитиниба с непрерывным высвобождением

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200406

FZDE Discontinued

Effective date: 20220830